Recent investigations have centered on the intersection of GLP-1|GIP|GCGR agonist therapies and dopaminergic communication. While GIP stimulators are commonly employed for addressing type 2 diabetes, their emerging https://nad712383.ampedpages.com/emerging-gip-stimulators-and-dopamine-modulation-a-contextual-examination-68837814